Clinical Trials Directory

Trials / Conditions / Tislelizumab

Tislelizumab

24 registered clinical trials studyying Tislelizumab — 14 currently recruiting.

StatusTrialSponsorPhase
Not Yet RecruitingProspective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophag
NCT07531979
Tianjin Medical University Cancer Institute and HospitalPhase 2
RecruitingNeoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal
NCT07458529
Seventh Medical Center of PLA General HospitalPhase 2
RecruitingNephron-sparing Treatment of Tislelizumab + Nab-Paclitaxel for Renal Pelvic Cancer
NCT07233252
Tianjin Medical University Second HospitalPhase 2
Active Not RecruitingIntestinal Low-Dose Radiotherapy Plus Immunochemotherapy for Conversion of Borderline Resectable/Unresectable
NCT07339488
Chuangzhen ChenPhase 2
RecruitingA Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cance
NCT07136077
M.D. Anderson Cancer CenterPhase 2
Not Yet RecruitingTislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer(TitAN) :
NCT07089199
Qilu Hospital of Shandong UniversityPhase 2
RecruitingCombination of Concurrent Chemoradiotherapy With Surufatinib and Tislelizumab in Patients With Locally Advance
NCT07086456
Sun Yat-sen UniversityPhase 2
RecruitingNeoadjuvant Tislelizumab + Nab-Paclitaxel Followed by Distal Ureterectomy for Ureteral Cancer
NCT07125547
Tianjin Medical University Second HospitalPhase 2
Not Yet RecruitingFruquintinib Combined With PD-1 Inhibitor and FOLFOX as First-Line Treatment For Advanced Gastric Cancer
NCT06871527
Sixth Affiliated Hospital, Sun Yat-sen UniversityPhase 1 / Phase 2
CompletedPhase II Study of Moderate-dose Hypofractionated RT Combined With Tislelizumab for HCC With Diffuse Tumor Thro
NCT06233981
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2
RecruitingTislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Sing
NCT07085182
Zibo Municipal HospitalPhase 2
UnknownCombination Therapy of HAIC, Surufatinib and Tislelizumab for Unresectable or Metastatic Biliary Tract Cancer
NCT06134193
Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyPhase 2
RecruitingXELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC
NCT05970302
Cancer Institute and Hospital, Chinese Academy of Medical SciencesPhase 2
RecruitingLenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage I
NCT05920863
Zhejiang Cancer HospitalPhase 2
Not Yet RecruitingTislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H/dMMR Stage II or III C
NCT05841134
The First Affiliated Hospital of Zhengzhou UniversityPhase 2
UnknownChemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC
NCT05394415
Jiangsu Cancer Institute & HospitalPhase 1 / Phase 2
UnknownTislelizumab and Radiotherapy for Recurrent Cervical Cancer
NCT05310383
Lei LiPhase 2
UnknownTislelizumab Combined With Chemotherapy in the Treatment of Bone Metastases of Unknown Primary
NCT05241132
Wei XuPhase 2
RecruitingPhase II, Single-arm Exploratory Clinical Study of Tislelizumab Combined With Anlotinib in the Treatment of Ad
NCT05375734
Second Affiliated Hospital of Nanchang UniversityPhase 2
Active Not RecruitingTotal Neoadjuvant Treatment Plus PD-1 in Mid-Low Locally Advanced Rectal Cancer
NCT04906044
The First Hospital of Jilin UniversityPhase 1
RecruitingReal World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Com
NCT07198217
Zibo Municipal HospitalPhase 2
UnknownClinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizuma
NCT05131698
Cancer Hospital of Guangxi Medical UniversityEARLY_Phase 1
UnknownPredictive Biomarker for Efficacy and Safety of Combination of Chemotherapy and Tislelizumab in NSCLC
NCT05244837
Hao LongPhase 2
UnknownTislelizumab Combined With Chemotherapy in First-line Treatment of AGC
NCT06034964
Cancer Institute and Hospital, Chinese Academy of Medical Sciences—